GLP-1 receptor agonists and SGLT2 inhibitors are recommended in the medical management of patients with type 2 diabetes and peripheral artery disease due to their cardiovascular benefits.
What is the optimal medical management for individuals with T2DM and lower extremity PAD in the era of GLP-1RA and SGLT2i?
This review highlights the importance of a multidisciplinary approach and the incorporation of GLP-1RA and SGLT2i in the medical management of patients with T2DM and lower extremity PAD to achieve cardiovascular benefits.
Lower extremity peripheral artery disease (PAD) often results from atherosclerosis, and is highly prevalent in patients with type 2 diabetes mellitus (T2DM). Individuals with T2DM exhibit a more severe manifestation and a more distal distribution of PAD compared to those without diabetes, adding complexity to the therapeutic management of PAD in this particular patient population. Indeed, the management of PAD in patients with T2DM requires a multidisciplinary and individualized approach that addresses both the systemic effects of diabetes and the specific vascular complications of PAD. Hence, cardiovascular prevention is of the utmost importance in patients with T2DM and PAD, and encompasses smoking cessation, a healthy diet, structured exercise, careful foot monitoring, and adherence to routine preventive treatments such as statins, antiplatelet agents, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. It is also recommended to incorporate glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in the medical management of patients with T2DM and PAD, due to their demonstrated cardiovascular benefits. However, the specific impact of these novel glucose-lowering agents for individuals with PAD remains obscured within the background of cardiovascular outcome trials (CVOTs). In this review article, we distil evidence, through a comprehensive literature search of CVOTs and clinical guidelines, to offer key directions for the optimal medical management of individuals with T2DM and lower extremity PAD in the era of GLP-1RA and SGLT2i.
Mahé et al. (Wed,) conducted a review in Type 2 diabetes mellitus and lower extremity peripheral artery disease. GLP-1 receptor agonists and SGLT2 inhibitors was evaluated. GLP-1 receptor agonists and SGLT2 inhibitors are recommended in the medical management of patients with type 2 diabetes and peripheral artery disease due to their cardiovascular benefits.